期刊文献+

hClock-(35-47)的表达、纯化及其功能的检验 被引量:2

Expression,Purification of hClock(35-47) and Verification of Its Transmembrane Ability in Vitro
下载PDF
导出
摘要 目的构建hClock-(35-47)的表达质粒,进行诱导表达,纯化,在体外初步鉴定其跨膜功能。方法合成hClock-(35-47)全长DNA序列,重组入pET-32a表达载体中,测序鉴定后转化入大肠杆菌Rosetta(DE3)菌株,构建好重组体的表达菌株。IPTG诱导并优化表达后,以NTA-Ni亲合层析进行分离纯化,及SDS-PAGE和Western bloting鉴定。纯化鉴定后的hClock-(35-47)用FITC标记,以一定的浓度孵育体外培养的血管内皮细胞(ECV-304),荧光显微镜下观察其穿膜活性。结果成功构建了hClock-(35-47)的表达载体,插入片断为51bp,表达产物相对分子质量约为21kD,经Western bloting鉴定,与抗His-Tag抗体有特异性反应,与培养的ECV-304孵化,显示具有穿膜功能。结论原核表达的hClock-(35-47)仍然保留其穿膜功能,为进一步研究提供基础。 Objective To clone, express and purify hClock-(35-47) and to verify its transmembrane ability in vitro, Methods cDNA sequence coded full-length hClock-(35-47) was synthesized and cloned into the expression plasmid pET-32a. After sequence analysis, the recombinants were transduced into E. coil Rosetta(DE3), which was induced with IPTG to express hClock-(35-47), The products were purified by NTA-Ni affinity chromatography and then verified by means of SDS-PAGE and Western blotting, The vascular endothelial cell (ECV-304) was cultured with hClock-(35-47) which had been labeled with FITC in vitro, and was observed through fluorescence microscope to examine the transmembrane ability of hClock-( 35-47 ), Results The hClock-(35-47) expression vector containing the insert of 51 bp was successfully constructed, The product is about 21 kD, which could react immunologically with standard anti-His-Tag antibody, Fluorescence microscopy showed that hClock-(35-47) has the ability to transfer into ECV-304 cells, Conclusion The recombinants hClock- (3547) expressed by E. coli. Rosetta( DE3)remain its transmembrane ability, Its large-scale preparation will be helpful for further studies.
出处 《航天医学与医学工程》 CAS CSCD 北大核心 2007年第4期250-253,共4页 Space Medicine & Medical Engineering
基金 国家自然科学基金资助项目(30070278 39970275)
关键词 hClock-(35-47) 纯化 内皮细胞 穿膜功能 hClock-(35-47) purification endothelial cells transmembrane ability
  • 相关文献

参考文献10

  • 1彭涛,杨春蕾,肖静,郭慧玲,刘英辉,王正荣.一种新的人源性穿膜肽[J].航天医学与医学工程,2003,16(5):368-370. 被引量:5
  • 2FAN Yongfeng, LU Chuanzhen, QIAO Jian, et al. Expressing,purifying of PTD-calbindin D28K fusion protein- and verifying Its transmembrane ability in vitro[ J ]. Fudan Univ J Med Sci, 2004, 31 (3): 231-234.
  • 3Makoff AJ,Oxer MD, Romanos MA, et al. Expression of tetanus toxin fragment C in E. coli: high level expression by removing rare codons [ J]. Nucleic Acids Res, 1989, 17(10) : 10191-10202.
  • 4Sorenson MA, Kurland CG, Pedersen S. Codon usage determines translation rate in escherichia coli[ J ]. J Mol Biol, 1989, 207(2) : 365-377.
  • 5Chen GFT, Inouye Mo Suppression of the negative effect of minor arginine codons on gene expression: preferential usage of minor codons within the first 25 codons of the Escherichia coli genes[J]. Nucleic Acids Res,1990,18(6) : 1465-1473.
  • 6Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus[J]. J Biol Chem,1997, 272 (25) : 16010-16017.
  • 7Derossi D, Joliot AH, Chassaing G, et al. The third helix of the antennapedia homeodomain translocates through biological membranes [ J]. J Biol Chem, 1994, 269 (14) : 10444-10450.
  • 8Elliott G, O' Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein [J ]. Cell, 1997,88 (2):223-233.
  • 9Astriab-Fisher A, Sergueev D, Fisher M, et al. Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, binding to target sequences, and biologic actions[ J ]. Pharm Res, 2002, 19 (6) : 744-754.
  • 10Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides[J]. J Biol Chem, 2001, 276 (8): 5836-5840.

二级参考文献1

共引文献4

同被引文献57

  • 1王莉,孟刚,牛微,杨空明,徐文岳,赵婷婷,唐艳,赵建平,吴玉章.CPP Tat_(49-57)促进外源CTL表位进入MHC-Ⅰ类抗原呈递途径的机制研究[J].免疫学杂志,2006,22(3):247-251. 被引量:4
  • 2刘秋英,王一飞,熊盛,张美英,钱垂文,何旭君.TAT-NDPK-A蛋白的构建表达及穿膜初步研究[J].中国药学杂志,2007,42(9):652-655. 被引量:2
  • 3黄莉莉,邵启祥,张慧,许逊,宗杨勇,陈述,申卫红,田小雷,彭鑫,王胜军,许化溪.PTD-Foxp3融合蛋白的表达、纯化及其生物学功能初步研究[J].江苏大学学报(医学版),2007,17(3):188-192. 被引量:6
  • 4Vives E. Present and future of cell-penetrating peptide mediated delivery systems:"is the trojan horse too wild to go only to troy? " [J]. J Control Release, 2005, 109(1-3): 77-85.
  • 5Hansen M, Kilk K, Langel U, et al. Predicting cell-penetrating peptides [J]. Adv Drug Deliv Rev, 2008, 60(4-5) : 572-579.
  • 6Green M, Loewenstein P M. Autonomous functional domains of chemically synthesized human immunodeficiency virus TAT transactivator protein [J]. Cell, 1988, 55(6): 1179-1188.
  • 7Green M, Ishino M, Loewenstein P M. Mutational analysis of HIV-1 TAT minimal domain peptides: identification of trans-domaint mutants that suppress HIV-LTR-driven gene expression[J]. Cell, 1989, 58 ( 1 ) :215-223.
  • 8Juliano R. Review of cell penetrating peptides: processes and applications[J]. J Control Release, 2003, 93(1): 88-89.
  • 9Zorko M, Langel U. Cell-penetrating peptides: mechanism and kinetics of cargo delivery [J]. Adv Drug Deliv Rev, 2005, 57(4) : 529-545.
  • 10Elmquist A, Hansen M, Langel U, Structure-activity relationship study of the cell-penetrating peptide pVEC [ J ]. Biochim Biophys Acta, 2006, 1758(6): 721-729.

引证文献2

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部